Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNT-HYPE in High-risk Extremity and Trunk Soft Tissue Sarcoma
NCT06835049Phase 2Recruiting
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Oct 2025
- Primary completion
- Mar 2028
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin, ifosfamide and dacarbazine in soft tissue sarcoma (STS), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoint: Protocol feasibility rate at 20 weeks. Started Oct 2025; status: recruiting.
02
Drugs
pegylated liposomal doxorubicinifosfamidedacarbazine
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT06835049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06835049.